Focus: Leo Cancer Care is a UK-based medical device company specializing in upright radiation therapy for oncology applications. The company is in Series B funding stage and has recently achieved FDA approvals for innovative cancer treatment devices.
Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago
Stable — net -2 jobs in 30d
3 added, 5 removed. Backfill posture.
A high-risk, high-reward opportunity for those betting on novel radiation oncology technology with recent regulatory wins, but lacking pipeline depth and financial transparency for risk-averse candidates.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
First-of-its-kind FDA-approved device for pancreatic cancer treatment demonstrates clinical differentiation and market entry validation.
Help build intelligence for Leo Cancer Care
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Leo Cancer Care's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second FDA approval in 2 weeks under expedited NPV program indicates strong regulatory pathway and unmet clinical need recognition.
Marie by Leo Cancer Care Achieves its First in Compact Upright Proton Therapy at Stanford Medicine - World Business Outlook
Marie by Leo Cancer Care Achieves its First in Compact Upright Proton Therapy at Stanford Medicine World Business Outlook
Marie® von Leo Cancer Care schreibt Geschichte am Stanford Medicine – Weltneuheit bei der kompakten Protonentherapie in aufrechter Position - Eagle-Tribune
Marie® von Leo Cancer Care schreibt Geschichte am Stanford Medicine – Weltneuheit bei der kompakten Protonentherapie in aufrechter Position Eagle-Tribune
Marie® de Leo Cancer Care entre dans l'histoire à Stanford Medicine – Une première mondiale dans le domaine de la protonthérapie compacte en position verticale - New Castle News
Marie® de Leo Cancer Care entre dans l'histoire à Stanford Medicine – Une première mondiale dans le domaine de la protonthérapie compacte en position verticale New Castle News
Marie® by Leo Cancer Care Makes History at Stanford Medicine — World First in Compact Upright Proton Therapy - Eagle-Tribune
Marie® by Leo Cancer Care Makes History at Stanford Medicine — World First in Compact Upright Proton Therapy Eagle-Tribune
FDA Issues Draft Guidance to Cut Unnecessary Animal Testing for Cancer Drugs
The U.S. Food and Drug Administration today issued a draft guidance to reduce unnecessary animal testing in nonclinical safety assessments for certain cancer drugs.
FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
FDA issued an approval for Bizengri (zenocutuzumab-zbco), a drug that treats NRG1 fusion-positive cholangiocarcinoma, an ultra-rare, aggressive cancer that forms in the bile ducts.
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Upright versus supine positioning for breast and lung radiotherapy: a pilot study on patient comfort, experience and lung function.
A low-cost, flexible, and accurate technique to study new immobilisation systems for radiotherapy and their 2D in-plane positional reproducibility and stability.
Showing 5 of 10 publications